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Abstract
Background: People in treatment for substance use disorder commonly have comorbid personality disorders,
including antisocial personality disorder. Little is known about treatments that specifically address comorbid antisocial
personality disorder.
Methods: Self-rated help received for antisocial personality disorder was assessed during follow-ups at 3, 9 and 15
months post-randomization of a randomized trial of psychoeducation for people with comorbid substance use and
antisocial personality disorder (n = 175).
Results: Randomization to psychoeducation was associated with increased perceived help for antisocial personality
disorder. Perceived help for antisocial personality disorder was in turn associated with more days abstinent and higher
treatment satisfaction at the 3-month follow-up, and reduced risk of dropping out of treatment after the 3-month
follow-up, and perceived help mediated the effects of random assignment on days abstinent at 3-month.follow-up.
Conclusions: Brief psychoeducation for antisocial personality disorder increased patients’ self-rated help for antisocial
personality disorder in substance abuse treatment, and reporting having received help for antisocial personality disorder
was in turn associated with better short-term outcomes, e.g., days abstinent, dropout from treatment and treatment
satisfaction.
Trial registration: ISRCTN registry, ISRCTN67266318, retrospectively registered 17/7/2012.
Keywords: Antisocial personality disorder, Substance use disorder, Perceived help, Randomized trial, Impulsive lifestyle
counselling
Background
Common mental health problems like depression and
anxiety often co-occur with problematic alcohol and
drug use [1–3], as do personality disorders, in particular
antisocial personality disorder [ASPD] [4, 5]. These co-
morbid conditions are associated with lower quality of
life for patients [6], and may also interfere with treat-
ment or with social rehabilitation [7, 8].
There is now increasing evidence that providing onsite
treatment in community substance abuse treatment that
targets comorbid conditions can benefit patients in a
range of settings, and that this applies to both substance
use and symptoms of anxiety and depression [9–12].
However, given that ASPD is one of the most common
comorbidities in illicit drug use disorder [DUD], it is
surprising that so little research has been conducted to
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assess ways to address ASPD in substance use disorder
[SUD] treatment settings, or to improve the outcomes
for patients with comorbid ASPD. This is especially sur-
prising, since ASPD may have an impact on the comple-
tion of treatment, although the impact depends on the
context surrounding the treatment episode, i.e., patients
with ASPD drop out when they have no tangible rewards
to gain from treatments [13]. When patients do not have
any tangible rewards to gain from being in treatment,
the challenge for clinicians is to help patients see that
treatment has relevance for them.
Impulsive lifestyle counselling
One intervention designed to improve the outcomes of
treatment for SUD in patients with ASPD, the Impulsive
Lifestyle Counselling [ILC] program [14], was developed
and tested in a pragmatic randomized trial. The trial
found that ILC had significant effects on days abstinent
from substance use and severity of drug use at the 3-
month follow-up, and that aggression declined in both
treatment as usual and ILC with no significant differ-
ences between interventions [15], and that the ILC pro-
gram had significant effects on the risk of dropout from
substance abuse treatment [16]. However, one question
that has not been previously assessed in this study is the
perceived helpfulness of treatments for mental health co-
morbidity. In general population studies, the perceived
helpfulness of treatments for depression is sometimes
assessed, usually through Likert scale items (e.g. [17, 18]),
but research is scarce. Examining perceived helpfulness of
treatment offers is important, as individual attitudes and
beliefs about treatment can influence future service use
and treatment seeking behavior [19]. For example, previ-
ous studies show that perceiving treatment as ineffective
is one of the commonly cited barriers deterring individuals
from seeking further treatment [20]. Perceived helpfulness
may be even more important for people with ASPD, since
patients with ASPD are prone to anger, and often find
themselves in conflicts with others, including clinic staff
[21]. Patients with any psychiatric disorder who enter
treatment have to face considerable challenges to engage
and remain in treatment. Usually, patients with psychiatric
disorders have lived a life with critical or concerned family
members, while at the same time experiencing a substan-
tial degree of self-criticism. Enrolling in treatment often
involves further challenges to the individual patient’s belief
systems. In addition, treatment is likely to focus on the
need to change coping strategies, which may be perceived
by the patient as a form of help for dealing with the
present, but may be ineffective in the long-term [22]. In
this context, people who are involved with drugs and
crime often have strong social bonds with others who use
drugs and break the law, and may have value systems that
conflict with collaborating with anyone who can be
regarded as being authority figures, both factors which
further complicate the treatment process [23]. At the
same time, patients with DUD need to contemplate get-
ting by without the drugs that have not only helped them
cope with daily hassles, and which have also become a
central part of their identity. As a consequence, entering
into treatment becomes a difficult transition that requires
a substantial amount of confidence in treatment; support-
ing that confidence is a key task for the treatment pro-
viders. Feeling that treatment is relevant and helpful may
give the patients motivation to engage more in treatment
and cooperate better with clinicians.
Aims
The aims of this study were to assess perceived help for
ASPD using secondary analyses based on a randomized
clinical trial of six sessions of psychoeducation for co-
morbid SUD and ASPD [15, 16]. We predicted that
randomization to the psychoeducational program would
increase the perception of having received help for
ASPD as part of the substance abuse treatment during
the study period. Finally, a third aim was to assess
whether self-rated help for ASPD mediated the effects of
the ILC program in this sample.
Methods
Study design for the ILC study
The ILC study was a Phase I pragmatic randomized
controlled trial with single blind assessments that was
carried out at community-based outpatient substance
abuse treatment clinics in Denmark between January
2012 and July 2014. The details of the study are re-
ported in two previous reports [15, 16]. Inclusion
criteria to the study were: between 18 and 65 years
old; met criteria for ASPD using the Mini Inter-
national Neuropsychiatric Interview [24]; and able to
provide written informed consent; seeking treatment
or already in treatment for a SUD.
Ethics, consent and permissions
The present project was reviewed by the regional ethics
committee of the Capital Region of Denmark and
deemed exempt from a formal evaluation (J#H-3-2012-
FSP45). The trial was registered in the ISRCTN register
(#ISRCTN67266318). All participants gave written and
verbal consent to participation and to be contacted for
follow-up interviews.
Recruitment and randomization
Study participants were identified by clinicians at the
participating sites from new and existing patients receiv-
ing outpatient community treatment for a SUD. After
agreeing to be contacted, a trained clinician at each site
invited potential participants to take part in a screening
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to assess the diagnosis of ASPD. Those who met inclu-
sion criteria were told that their responses indicated
ASPD, and the clinician would then review their responses
to the ASPD MINI module with the patients, and ask if
they were willing to talk to a trained ILC counsellor about
it. Patients who agreed to see a counsellor and who pro-
vided written informed consent, subsequently completed
the baseline assessment and were randomly allocated to
either one of two treatment groups: treatment as usual
(TAU) or the Impulsive Lifestyle Counselling (ILC).
Randomization was stratified by clinic. The
randomization schedules were generated by the trial co-
ordinator and kept secure and confidential by the trial
coordinator at the study coordinating center in
Copenhagen. The trial coordinator informed the refer-
ring clinician of the result of randomization immediately
after being notified that the patient had been assessed
and found to be eligible for study participation. Follow-
ing this, the clinician informed the patient of the result.
In cases in which the patients were randomized to the
ILC program, the clinician contacted one of the ILC
counsellors at the uptake unit with the participants’ de-
tails so that the program sessions could be initiated im-
mediately after randomization.
Because the randomization took place immediately
after the screening interview, the trial coordinator was
unable to check whether the baseline assessment was
complete before randomizing, and patients with incom-
plete data at baseline were excluded after randomization.
Treatment conditions
Treatment as usual (TAU)
All participants received whichever form of treatment
they would have received at the participating treatment
service if the trial had not taken place. Treatment always
included access to opioid substitution treatment for pa-
tients who needed it, either with methadone, buprenor-
phine or a combination of methadone and injectable
diacetylmorphine; psychosocial support in the form of
casework and counselling; and referral to residential re-
habilitation for patients who needed it. At some clinics,
a liaison psychiatrist would see the patients onsite,
whereas patients in other clinics would be referred to an
off-site psychiatrist for diagnosis and treatment of other
psychiatric conditions, such as attention-deficit/hyper-
activity disorder, anxiety or depression.
Impulsive Lifestyle Counselling (ILC)
In addition to the services available to the patients who
received TAU, patients randomized to ILC were offered
up to six one-hour ILC sessions. The ILC program is a
highly structured workbook on psychoeducational inter-
vention for people with ASPD [14]. The form and con-
tent of the sessions were adapted from the manual for
the Lifestyle Issues Program [25], and in line with the
Lifestyle Issues Program, the main objective of the ILC
program is to support the individual patient in awareness
raising, in taking responsibility for addressing behavioral
problems, and in opening up to the possibility of a change
of lifestyle. Further, similar to the psychoeducational ap-
proach by Banerjee and colleagues, the psychoeducational
approach in the ILC is intended to function as an educa-
tive and collaborative exercise that can improve patient
engagement in further treatment [26, 27].
The first five sessions takes place once a week; each
session covers a specific topic, and includes specific
questions that the counsellor asks, as well as pre-printed
handouts and worksheets given to the patient. The first
session focuses on the objective of the ILC program, and
on identifying thoughts and behaviors related to ASPD.
The second session is based on an adapted version of the
Antecedents-Beliefs-Consequences model from Rational-
Emotive Behavior Therapy [28], linking the patients’ im-
pulsive behaviors to the immediate consequences. Session
3 focuses on how impulsive and destructive behaviors are
related to specific value systems and beliefs related to
ASPD, and Session 4 presents the concept of values and
discusses what values may support or prevent the patient
in change of lifestyle. Session 5 focuses on the patient’s so-
cial networks and how social contacts may support or
challenge lifestyle changes. The last session is a booster
session that takes place 6 weeks after Session 5, at which
the patient is invited to talk about the topics from the pre-
vious five sessions that he or she finds most relevant for
future work with lifestyle changes.
Like the Lifestyles Issues Program, the ILC program is
designed so that no prior professional training or special
facilities of any sort are necessary in order for the inter-
vention to be feasible in most clinical settings where
people with DUD receive treatment. However, prior to
delivering the study intervention, all counsellors partici-
pated in a one and a half day workshop to practice the
workbook and discuss issues relating to treating people
with ASPD in general. All counsellors were required to
both keep written records and make audio recordings of
the sessions.
Follow-up procedures
For the three follow-up waves at 3, 9 and 15 months
after randomization, patients were contacted first
through any phone number they had provided. If it was
not possible to establish contact using this procedure,
the patient was contacted through the clinic at which he
or she had been screened for study participation. If a pa-
tient still could not be reached, researchers would ask
his or her case manager at the study clinic if they could
set up a time for a meeting, or when it would be feasible
to meet the patient. Patients who could still not be
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reached this way were contacted through the contact in-
formation that they had provided to significant others,
and finally through other accessible services (e.g. prison
or psychiatry). In a few cases, the patients were eventu-
ally located through the Central Personal Register. Once
a patient had been located, and if it was possible to
speak with the patient directly, a place and time for an
interview was scheduled. If the patient did not show up
for a face-to-face interview, a new time would be sched-
uled, and only after several failed attempts was a tele-
phone interview suggested. If the patients stated that
they were not willing to be interviewed, they would be
asked if they would agree to be contacted at a later
point, and if they refused, they were not contacted again.
Measures
The primary outcome variable for the present study was
the degree to which respondents reported having re-
ceived help for ASPD. In this article, we refer to this as
“self-rated help for ASPD”.
In order to assess perceived help, two Likert scale
questions were asked. First, respondents were asked if
they believed they had, or had had, ASPD while they
were in treatment, with response options 3 = definitely, 2
= probably, 1 = probably not, and 0 = not at all. Inter-
viewers were instructed to refer to the MINI adult ASPD
items which were included on the questionnaire. Per-
ceived help for each disorder was measured by asking re-
spondents if they had received any form of help for the
ASPD during the course of SUD treatment. Here response
options were 3 = having received help to a very high de-
gree, 2 = having received help to some degree, 1 = having
received a little help, and 0 = not having received help.
Diagnosis of ASPD
The Mini International Neuropsychiatric Interview
[MINI] was used to screen for ASPD [29, 30]. The MINI
was designed to assess DSM-IV and ICD-10 diagnoses
[29, 30], and is a fully structured, brief and valid diag-
nostic interview that can be conducted by a lay person,
and is well accepted by patients [31]. The ASPD module
consists of six questions concerning childhood conduct
disorder and six questions about adult ASPD. Previous
research indicates that the MINI module for ASPD iden-
tifies prison inmates with more serious mental health
problems, more substance abuse problems and a more
serious and chronic history of offending behavior as
compared with other inmates [32–34], and that ASPD
diagnosed according to the MINI is associated with illicit
drug use in the general population [35].
Additional demographic data were collected on a sep-
arate sheet, including education, employment history
and history of homelessness, residential treatment for
SUD, incarceration and psychiatric hospitalizations.
Current substance use severity was measured using
the drug use composite score from the Addiction Sever-
ity Index (ASI), of which has demonstrated high con-
cordance with DSM-IV SUDs [36].
Internal consistency for the drugs composite score in
this sample was α = 0.60 at baseline, α = 0.60 at the 3-
month follow-up, and α = 0.64 at the 9-month follow-up.
A second outcome measure was days abstinent in the
past 30 days. All substance use data were collected at
baseline and at each follow-up wave.
General aggression was measured using the 12-item ver-
sion of the Buss-Perry Aggression Questionnaire (BPAQ,
[37]), a commonly used measure of general aggression in
both general population and forensic samples with good
psychometric properties. Sample items include statements
such as: “Given enough provocation, I may hit another
person.” and “I often find myself disagreeing with people.”
The items are scored on a five-point Likert scale ranging
from 1 (“extremely uncharacteristic of me”) to 5 (“ex-
tremely characteristic of me).” Sample internal consistency
for the BPAQ was α = 0.82 at baseline, α = 0.81 at the 3-
month follow-up, α = 0.80 at the 9-month follow-up, and
α = 0.81 at the 15-month follow-up.
Interpersonal aggression was measured using the 14-
item version of the Self-Report of Aggression and Social
Behavior Measure (SRASBM, [38]) a measure of inter-
personal aggressive acts and dispositions. Sample items
include statements such as: “My friends know that I will
think less of them if they do not do what I want them to
do.” and “When I am mad at a person, I try to make
sure she/he is excluded from group activities (such as
going to the movies or to a bar).” Items are rated on a
five-point Likert scale from 0 (“Never”) to 4 (“Very
often”). The internal consistency for the SRASBM in this
sample was α = 0.78 at baseline, α = 0.81 at the 3-month
follow-up, α = 0.82 at the 9-month follow-up, and α =
0.82 at the 15-month follow-up.
Treatment satisfaction was assessed using the 8-item cli-
ent satisfaction questionnaire (CSQ, [39]). The internal
consistency for the CSQ was α = 0.90 at baseline, α = 0.94
at the 3-month follow-up, α = 0.95 at the 9-month follow-
up, and α = 0.96 at the 15-month follow-up.
Blinding
Research technicians not affiliated with the study clinics
carried out all assessments at the follow-up interviews
and were blind to treatment group allocation.
Analyses
Random-effects regression was used assess to the likeli-
hood of a high versus low endorsement of having re-
ceived help for ASPD during the three follow-up waves.
Random effects were estimated for both patient and study
site, and covariates were gender, age, receiving substitution
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treatment at baseline, treatment satisfaction at baseline
and assessment wave (3 months being the reference cat-
egory, and 9 and 15 months being the dummy codes).
The study applied intent-to-treat analyses, i.e. data
were analyzed by randomization arm irrespective of at-
tendance or treatment compliance. Covariates were
gender, age, receiving substitution treatment at baseline,
and assessment wave (3 months being reference, 9 and
15 months being dummy codes). The predictor was
randomization status.
Following this, random-effects regression analysis was
conducted for each of the primary outcomes of the trial,
to test whether self-rated treatment for ASPD was asso-
ciated with improved outcomes for the trial. In each of
these analyses, the predictors were: perceived help for
ASPD, age, gender, substitution at baseline and the base-
line value for the outcome of interest, and random ef-
fects were estimated for study site and patient.
An identical random effects regression was conducted
for global treatment satisfaction, defined in the trial
registration as a secondary outcome. Survival analysis
was used to assess whether perceived help for ASPD was
associated with risk of subsequent dropout from the 3-
month follow-up using Cox proportional hazards regres-
sion with clustering for site, again adjusted for gender,
age and substitution treatment at baseline. Of the 128
patients who were interviewed at the 3-month follow-
up, 18 had been discharged from treatment, and were
thus no longer at risk of dropping out. Therefore, the
survival analysis was conducted using the remaining 110
patients.
Finally, we intended to test whether self-rated help for
ASPD mediated the effects of the ILC program on our
two significant outcomes, days abstinent and ASI drugs
composite score, we conducted two mediation analyses.
First, we assessed whether effects of the ILC program on
self-rated help for ASPD mediated the effects of ILC on
days abstinent, and then we assessed whether the effects
of the ILC program on self-rated help for ASPD medi-
ated the effects of ILC on the drugs composite score
[15]. In mediation analysis, some of the effect of the in-
dependent variable, the IV, is transmitted to the
dependent variable, the DV, through the mediator vari-
able, the MV and some of the effect of the IV passes dir-
ectly to the DV. Mediation occurs when the following
four statements are true: (1) the IV has significant effects
on the DV; (2) the IV has significant effects on the MV;
(3) the MV has significant effects on the DV; and (4)
once the effects of the MV on the DV are controlled, the
effect of the IV on the DV is significantly reduced [40].
In the mediation analyses, the IV was randomization sta-
tus (ILC or TAU), the MV was self-rated help, and the
DV was days abstinent in the first analysis, and the ASI
drugs composite score in the second. In both mediation
analyses, baseline values for the DV, substitution treat-
ment, age and gender were included as control variables.
We present the results of a power analysis to detect a
significant mediation effect based on Thoemmes, Mack-
innon & Reiser [41]. The presented analysis is based on
the observed effects in this study, and was adapted from
Thoemmes and colleagues’ work using MPlus 7.4. Spe-
cifically, we retained the a and b coefficients (i.e., the ef-
fect of ILC on perceived help and the effect, and the
effect of perceived help on days abstinence), as these
two are the only ones that are of consequence for the
power analysis [42].
To assess the mediation effect, we used the Preacher
and Hayes method. The indirect effect was obtained
with 5,000 bootstrap resamples [43]. The mediation ana-
lyses were conducted using only when both the IV (ran-
dom assignment) and the MV (self-rated help for ASPD)
had significant on the outcome of interest, as mediation
cannot occur when either the direct effect of the IV or
the MV is not statistically significant.
Results
Participants
Characteristics of the patients randomized to each of the
two conditions are summarized in Additional file 1:
Table S1. The 175 participants were 156 men and 19
women, the mean age was 32.4 years of age (standard
deviation [SD] = 9.0), and 38.3% were receiving opioid
substitution treatment at the time of randomization.
Follow-up rate
Of 175 patients randomized, 130 were interviewed at 3
months (74%), 118 at 9 months (67%), and 107 at 15
months (61%). Of these, a small number of respondents
(ranging from 2 to 12 respondents at each follow-up
wave), did not respond to the question about self-rated
help for ASPD. The main reason that respondents did not
answer the item was that the informant had to be inter-
viewed by telephone, and in the telephone interviews, we
asked only about the primary outcomes for this study.
When patients had not responded to an item at a given
follow-up wave, they were excluded from the analysis of
that variable at that point.
Perception of having received help for ASPD
The ratings of help for ASPD are summarized in Fig. 1.
As can be seen in Fig.1, regardless of randomization as-
signment, a very large proportion of patients reported
that they did not receive any help for ASPD at all.
The mixed effects regression is summarized in Table 1.
The primary aim of this analysis was to test whether the
intervention had a direct effect on self-rated help.
Higher scores on help for ASPD were associated with
randomization to ILC (p < .001), and older patients gave
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lower scores on having received help for ASPD (p
= .016). No other covariates were significant. The intra-
class correlation for site was small (ρ = .082, 95% CI
= .015–0.337), and the intraclass correlation for patient
was moderate (ρ = .415, 95% CI = .295–0.546).
Associations between self-reported help and primary
outcomes
The results of mixed regression analyses for self-
reported outcomes are summarized in Table 2. The re-
sults of these analyses were to test whether self-rated
help was associated with better outcomes.
Perceived help for ASPD was associated with more
days abstinent (B = 1.29, z = 2.32, p = .020), treatment
satisfaction (B = 0.079, z = 2.50, p = .012), and self-
reported general aggression on the BPAQ (B = 0.103, z =
2.13, p = .033). Associations with ASI drugs composite
score (B = 0.004, z = 0.81, p = .416), B = -0.002, z = -0.30,
p = .766), and interpersonal aggression (B = 0.027, z =
1.38, p = .169) were not statistically significant.
Association with secondary outcomes
Self-reported treatment for ASPD was associated with
higher satisfaction with treatment (B = 0.077, p = .015).
The survival analysis was significant (Wald χ2(4) = 13.83,
p = .008), and self-reported treatment for ASPD at the 3-
month follow-up was associated with lower risk of sub-
sequent dropout (Hazard ratio [HR] = 0.762, z = -2.27, p
= .023). In addition, age was negatively associated with
dropout (HR = 0.935, z = -2.02, p = .044) and substitution
treatment at baseline was negatively associated with sub-
sequent dropout (HR = 0.464, z = 2.08, p = .037).
Mediation analyses
The theoretical mediation analyses are summarized Fig. 2.
Following the convention in mediation analysis, the a co-
efficient is the effect of the IV, ILC, on the MV, perceived
help for ASPD. The b coefficient is the effect on the MV
on the DV, days abstinent or drugs composite score. The c
coefficient is the direct effect of the IV on the DV.
Given that only days abstinent satisfied the two first
criteria for mediation (direct effects of random assign-
ment and effect of MV on DV), we only analyzed medi-
ation for this variable. The results are summarized in
Table 3. Of the 128 patients who answered the question
about help for ASPD, four had not answered the items
about days abstinent at baseline, and had to be excluded,
Fig. 1 Self-rated help for ASPD. Response categories. 3 = having received help to a very high degree, 2 = having received help to some degree, 1
= having received a little help, and 0 = not having received help
Table 1 Predictors of self-rated help for antisocial personality
disorder (n = 149)
Coefficient P-value
Randomized to ILC 0.454 (0.195–0.713) .001
Conduct disorder item count 0.083 (-0.096–0.262) .363
Adult ASPD item count 0.136 (-0.005–0.277) .059
Assessment wave
9 months −0.042 (-0.256–0.173) .703
15 months 0.037 (-0.189–0.263) .746
Female gender −0.073 (-0.383–0.337) .726
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leaving 124 patients for this analysis. In the first step,
days abstinent at the 3-month follow-up was associated
with randomization to ILC (Z = 2.06, p = .042). In the
second step, perceived help was associated with
randomization to ILC (Z = 2.85, p = .005). In the third
step, perceived help was associated with more days ab-
stinent (Z = 2.17, p = .032), and randomization to ILC
was no longer significantly associated with days abstin-
ent (Z = 1.47, p = .144). For days abstinent, 27% of the ef-
fect of randomization was explained by self-rated help
for ASPD (observed indirect coefficient = 1.037, boot-
strap CI 0.050–2.600) and given that the CI does not
overlap with zero, the indirect effect was significant [43].
Power to detect mediation effects
A post-hoc power analysis was conducted to assess
mediation effects for the present study based on the
recommendations of Thoemmes, Mackinnon & Reiser
[41]. The analysis was based on the Mplus code for a
single mediator, and we substituted the values from
the present study for the values in their code. The analysis
showed that the indirect effect would be significant in
85.3% of replications with a sample of 124 patients. With
90 patients, 62.9% of tests would be significant, with
110 patients, 78.1% would be significant, ant with 140
patients, 91.4% would be significant. The Mplus output
is in Additional file 2.
Table 2 Associations between self-rated help for ASPD and outcomes (N = 149)




Help for ASPD 1.216 (0.161–
2.271)




0.024 (-0.014–0.062) 0.077 (0.016–
0.140)


















0.226 (-0.035–0.487) 0.082 (-0.040–0.205) −0.150 (-0.382–
0.083)
Female gender Ref. Ref. Ref. Ref. Ref. Ref.


















































Site .000 .000 .000 .000 .000 .000
Patient .509 (.404–.612) .043 (.321–.551 .307 (0.198–0.442) .360 (.252–.484) .502 (.377.–.626) .630 (.534–.718)
Notes
ASPD antisocial personality disorder
Coefficients significant at p < .05 are in boldface
Fig. 2 Theoretical mediation model
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Discussion
This study had three, related aims. First: to test if the ILC
program had an effect on perceived help for ASPD during
treatment. In line with the predictions, randomization to
the ILC program did increase the endorsement of the per-
ception of having received help for ASPD while in treat-
ment for a SUD. This is an important finding, because it
means that by offering brief psychoeducation, in this case
the ILC program, to patients with ASPD, it is possible to
increase the likelihood that they will feel that treatment
addresses a significant problem in their life.
In light of the fact that the intervention had an impact
on retention and abstinence as reported in previous arti-
cles, it is very encouraging that patient perceptions con-
verged with other findings in showing that the ILC
program increased the degree to which the SUD treat-
ment was perceived as helpful by the patients.
The second aim was to test if perceived helpfulness
was associated with better outcomes, adjusting for base-
line values. The findings concerning this aim were less
consistent: perceived help was associated with more days
abstinent, higher treatment satisfaction and decreased
risk of dropping out of treatment, but not with drug se-
verity, or self-reported interpersonal aggression. The link
between perceived help and outcomes may be import-
ant, even when this has nothing to do with the interven-
tion under study in this trial. If perceived help is
important for patients with ASPD, other interventions
that increase perceived help may be useful in improving
outcomes for patients with ASPD.
However, one outcome was negatively associated with
self-rated help: patients who rated higher on having re-
ceived help for ASPD reported more general aggression
at follow-up waves on the BPAQ. This finding may seem
paradoxical, as it is somewhat counterintuitive that
someone who has received more help for ASPD would
be more aggressive, while at the same time being more
satisfied with treatment and less likely to drop out of
treatment. One possible explanation is that patients who
remember having discussed issues related to offending,
impulsive and violent behavior may be more aware their
own aggression, or more willing to disclose aggressive
thoughts and behaviors to an interviewer.
In relation to the third aim, we were able to confirm
that perceived help for ASPD mediated the effects of our
intervention on only one of our primary outcomes. Our
study was not powered to test such an association a
priori, as the power analysis was conducted simply to as-
sess the likelihood of finding a significant effect of the
intervention [15]. The post hoc power analysis suggested
the study did have the power to detect a mediation ef-
fect. In order to have a reasonable likelihood of detecting
a significant mediation effect, the a and b paths must
both be of considerable size [41]. Indeed, in the present
study, the effect of random assignment on perceived
help (i.e., the a coefficient) and the association between
perceived help and days abstinent (i.e., the b coefficient),
were strong. However, this must be interpreted with great
caution, as it is possible that third variables confounded
the mediator and the dependent variable, a situation which
could bias the estimate of the indirect effect [44]. Clearly,
larger trials are needed to address potential mechanisms of
action, including mediation through perceived help.
Another important finding from this study is that
among the patients included in this trial, whenever an
interviewer asked them during the three follow-up waves
whether they had received help, a majority indicated that
they had received little if any kind of help for ASPD dur-
ing their treatment, regardless of whether they were ran-
domized to ILC or TAU. This is important, because it
indicates that being in treatment for a SUD in itself was
rarely perceived as help for ASPD. Also, while the brief
psychoeducational intervention increased the likelihood
that a patient would report help for ASPD slightly, it did
not change the perception of the majority of patients,
and much more work is needed to ensure that a sub-
stantial proportion of patients with ASPD get treatment.
Whether the statistically significant effect of ILC on
perceived help should be interpreted as patients perceiv-
ing the brief psychoeducational program as helpful in it-
self, or that it changed the way in which patients
evaluated their overall SUD treatment, cannot be
Table 3 Summary of mediation analysis
Days abstinent (n = 124)
Coefficient T-score P-value
a coefficient 0.53 2.85 .005
b coeffient 1.96 2.17 .032
c coefficient without mediator 3.81 2.06 .042
c coefficient with mediator 2.77 1.74 .144
Preacher and Hayes indirect effect 1.037 (0.050–2.600)
Z-score
Sobel 1.04 1.73 .084
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addressed based on the available data. Our questions did
not ask about the ILC program in relation to receiving
help for ASPD, only if they had received any help for
ASPD as part of their overall treatment.
A number of limitations must be acknowledged for
this study. First, the questions used to assess self-rated
ASPD and self-rated help for ASPD were not validated
prior to inclusion in this study. We are, however, aware
of no validated instruments to assess these issues, and
the question used to assess self-rated help was modelled
after questions used in epidemiological research. Sec-
ondly, although the study is not small in comparison to
other randomized studies of comorbid conditions in
populations with SUD, the sample size was too small to
address some very crucial research questions, such as
whether self-rated helpfulness mediated the link between
randomization status and self-rated ASPD.
Another substantial limitation is that we were able to
maintain only a small minority of our patients in psychoe-
ducation long enough to receive the full dose of psychoedu-
cation. Although only a few patients dropped completely
out of SUD treatment during the period where they were
meant to receive the psychoeducational intervention, many
missed appointments repeatedly or stopped showing up
altogether, so that they did not receive an optimal amount
of psychoeducation. This is a significant limitation of the
trial in general, and this trial has certainly not exhausted
the ways to improve services for people with ASPD.
Conclusions
Brief psychoeducation for antisocial personality disorder
increased patients’ self-rated help for antisocial personal-
ity disorder in substance abuse treatment, and patients’
self-reporting of having received help for antisocial per-
sonality disorder was in turn associated with better
short-term outcomes. Future research should maintain a
focus on the role of perceived help in the process and
outcomes of treatment, across various types of comorbid
conditions in patients with substance use disorders.
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